Antiproteasic agents in the prevention of post-ERCP pancreatitis: rationale for use and clinical results.

[1]  C. Bassi,et al.  Effectiveness of gabexate mesilate in acute pancreatitis , 1995, Digestive Diseases and Sciences.

[2]  T. Hayakawa,et al.  Prevention of experimental acute pancreatitis by intraduodenal trypsin inhibitor in rat , 1990, Digestive Diseases and Sciences.

[3]  T. Nevalainen,et al.  The role of phospholipase A2 in human acute pancreatitis , 1989, Klinische Wochenschrift.

[4]  P. Lankisch,et al.  Synthetic versus natural protease inhibitors in acute experimental pancreatitis , 1988, Digestive Diseases and Sciences.

[5]  S. Passaretti,et al.  Effects of Gabexate Mesilate, a Protease Inhibitor, on Human Sphincter of Oddi Motility , 2002, Digestive Diseases and Sciences.

[6]  W. Bechstein,et al.  [Acute pancreatitis]. , 2004, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

[7]  G. Costamagna,et al.  Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis , 2003, American Journal of Gastroenterology.

[8]  A. Kingsnorth,et al.  Cytokine storm in acute pancreatitis. , 2002, Journal of hepato-biliary-pancreatic surgery.

[9]  A. Andriulli,et al.  Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. , 2002, Gastrointestinal endoscopy.

[10]  T. Takada,et al.  Evidence-based clinical practice guidelines for acute pancreatitis: proposals. , 2002, Journal of hepato-biliary-pancreatic surgery.

[11]  Vijay P. Singh,et al.  Cathepsin B inhibition prevents trypsinogen activation and reduces pancreatitis severity. , 2002, American journal of physiology. Gastrointestinal and liver physiology.

[12]  K. Ohlsson,et al.  Enzyme Leakage, Trypsinogen Activation, and Inflammatory Response in Endoscopic Retrograde Cholangiopancreatography-Induced Pancreatitis , 2002, Pancreas.

[13]  N. Tanaka,et al.  Differential Cytokine Response in Host Defence Mechanisms Triggered by Gram-Negative and Gram-Positive Bacteria, and the Roles of Gabexate Mesilate, a Synthetic Protease Inhibitor , 2002, The Journal of international medical research.

[14]  S. Singh,et al.  Serum lipase, C-reactive protein, and interleukin-6 levels in ERCP-induced pancreatitis. , 2001, Gastrointestinal endoscopy.

[15]  H. Tsujimoto,et al.  Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor alpha production of monocytes. , 2001, Shock.

[16]  I. Sekine,et al.  Inhibitory effect of serine protease inhibitors on neutrophil‐mediated endothelial cell injury , 2001, Journal of leukocyte biology.

[17]  P. Testoni,et al.  Pain at 24 hours associated with amylase levels greater than 5 times the upper normal limit as the most reliable indicator of post-ERCP pancreatitis. , 2001, Gastrointestinal endoscopy.

[18]  H Lippert,et al.  Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. , 2000, The Journal of clinical investigation.

[19]  T. Hwang,et al.  Prospective and randomized study of gabexate mesilate for the treatment of severe acute pancreatitis with organ dysfunction. , 2000, Hepato-gastroenterology.

[20]  D. Noh,et al.  Effect of Protease Inhibitor on Ischemia-reperfusion Injury to Rat Liver , 1999, World Journal of Surgery.

[21]  J. Werner,et al.  Trypsin and activation of circulating trypsinogen contribute to pancreatitis-associated lung injury. , 1999, The American journal of physiology.

[22]  R. Pezzilli,et al.  Management of acute pancreatitis in clinical practice. ProInf - A.I.S.P. Study Group. Progetto Informatizzato Pancreatite Acuta--Associazione Italiana Studio Pancreas. , 1999, Italian journal of gastroenterology and hepatology.

[23]  J. Werner,et al.  Interstitial trypsinogen release and its relevance to the transformation of mild into necrotizing pancreatitis in rats. , 1999, Gastroenterology.

[24]  P. Testoni,et al.  Serum amylase measured four hours after endoscopic sphincterotomy is a reliable predictor of postprocedure pancreatitis , 1999, American Journal of Gastroenterology.

[25]  C. Bassi,et al.  Assessment and treatment of severe pancreatitis. Protease inhibitor. , 1999, Digestion.

[26]  T. Tadakuma,et al.  Inhibitory effect of protease inhibitor on endothelial cell activation. , 1998, The Journal of surgical research.

[27]  M. Lerch,et al.  Intra-acinar cell activation of trypsinogen during caerulein-induced pancreatitis in rats. , 1998, American journal of physiology. Gastrointestinal and liver physiology.

[28]  J. Schölmerich,et al.  Interleukins and their antagonists but not TNF and its receptors are released in post‐ERP pancreatitis , 1998, European journal of gastroenterology & hepatology.

[29]  P. Ascenzi,et al.  Effect of gabexate mesylate (FOY), a drug for serine proteinase-mediated diseases, on the nitric oxide pathway. , 1998, Biochemical and biophysical research communications.

[30]  Leandro,et al.  Meta‐analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis , 1998, Alimentary pharmacology & therapeutics.

[31]  M. Steer.  Frank Brooks memorial Lecture: The early intraacinar cell events which occur during acute pancreatitis. , 1998, Pancreas.

[32]  Y. Yamaguchi,et al.  Cerulein-induced in vitro activation of trypsinogen in rat pancreatic acini is mediated by cathepsin B. , 1997, Gastroenterology.

[33]  A. Fürstenberg,et al.  Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis. , 1997, Gut.

[34]  A. Mariani,et al.  Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group. , 1996, The New England journal of medicine.

[35]  S. Sherman,et al.  Early recognition of post-ERCP pancreatitis by clinical assessment and serum pancreatic enzymes. , 1996, The American journal of gastroenterology.

[36]  K. Takatsuki,et al.  Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting tumor necrosis factor production by monocytes. , 1996, Critical care medicine.

[37]  K. Federlin,et al.  Evaluation of ERCP- and endoscopic sphincterotomy-induced pancreatic damage: a prospective study on the time course and the significance of serum levels of pancreatic secretory enzymes. , 1996, European journal of medical research.

[38]  H. Reber,et al.  Cytokines and acute pancreatitis. , 1996, Gastroenterology.

[39]  C. Bassi,et al.  Effectiveness of gabexate mesilate in acute pancreatitis. A metaanalysis. , 1995, Digestive diseases and sciences.

[40]  T. Yoshida.  Gabexate mesilate in human acute pancreatitis. , 1993, Gastroenterology.

[41]  C. Bassi,et al.  Gabexate mesilate vs aprotinin in human acute pancreatitis (GA.ME.P.A.) , 1993, International journal of pancreatology : official journal of the International Association of Pancreatology.

[42]  M. Lerch,et al.  Pancreatic duct obstruction triggers acute necrotizing pancreatitis in the opossum. , 1993, Gastroenterology.

[43]  W. Creutzfeldt,et al.  Effect of Camostate Administration for Two Weeks on Experimental Pancreatitis in Mice and Rats , 1993, Pancreas.

[44]  M. Pérez-Mateo,et al.  Multicenter double-blind trial of gabexate mesylate (FOY) in unselected patients with acute pancreatitis. , 1992, Digestion.

[45]  N. Komi,et al.  [Effect of synthetic protease inhibitor on the sphincter of Oddi function in dogs]. , 1991, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

[46]  H. Harada,et al.  Clinical trial with a protease inhibitor gabexate mesilate in acute pancreatitis , 1991, International journal of pancreatology : official journal of the International Association of Pancreatology.

[47]  W. Creutzfeldt,et al.  Camostate (FOY-305) improves the therapeutic effect of peritoneal lavage on taurocholate induced pancreatitis. , 1990, Gut.

[48]  J. Meldolesi,et al.  Pancreatic duct obstruction in rabbits causes digestive zymogen and lysosomal enzyme colocalization. , 1989, The Journal of clinical investigation.

[49]  I. Renner,et al.  The effects of nafamostat mesilate (FUT-175) on caerulein-induced acute pancreatitis in the rat , 1989, International journal of pancreatology : official journal of the International Association of Pancreatology.

[50]  A. Saluja,et al.  Esterase inhibitors prevent lysosomal enzyme redistribution in two noninvasive models of experimental pancreatitis. , 1989, Gastroenterology.

[51]  K. Shibayama,et al.  Prevention of the spread of experimental acute pancreatitis by intraductal administration of a synthetic protease inhibitor in dogs. , 1989, The American journal of gastroenterology.

[52]  B. Göke,et al.  Effect of FOY-305 (camostate) on severe acute pancreatitis in two experimental animal models. , 1989, Gastroenterology.

[53]  L. Ferrell,et al.  Therapeutic regimens in acute experimental hemorrhagic pancreatitis. Effects of hydration, oxygenation, peritoneal lavage, and a potent protease inhibitor. , 1988, Gastroenterology.

[54]  A. Barrett,et al.  Possible lysosomal activation of pancreatic zymogens. Activation of both human trypsinogens by cathepsin B and spontaneous acid. Activation of human trypsinogen 1. , 1988, Biological chemistry Hoppe-Seyler.

[55]  L. Ferrell,et al.  Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis. , 1986, The Journal of clinical investigation.

[56]  M. D. de Santi,et al.  Pulmonary vascular injury in pancreatitis: evidence for a major role played by pancreatic elastase. , 1985, Experimental and molecular pathology.

[57]  I. Koh,et al.  Toxic products in hemorrhagic ascitic fluid generated during experimental acute hemorrhagic pancreatitis in dogs and a treatment which reduces their effect. , 1985, Digestion.

[58]  J. Meldolesi,et al.  Pancreatic effects of ethionine: blockade of exocytosis and appearance of crinophagy and autophagy precede cellular necrosis. , 1982, The American journal of physiology.

[59]  N. Ikei,et al.  Prevention of acute experimental pancreatitis in rats and dogs by intraduodenal infusion of a synthetic trypsin inhibitor. , 1982, Digestion.

[60]  Y. Tamura,et al.  Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r-, and C1 esterase. , 1977, Biochimica et biophysica acta.

[61]  A. Hirshkowitz,et al.  The activation of trypsinogen by cathepsin B. , 1959, The Journal of biological chemistry.